Myriad Genetics (MYGN) Inventory Average (2011 - 2026)

Myriad Genetics (MYGN) has reported Inventory Average for 16 consecutive years, with $29.2 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Inventory Average rose 4.84% year-over-year to $29.2 million; the TTM figure through Mar 2026 stood at $29.2 million (up 4.84% YoY), while the FY2025 annual figure was $29.0 million, up 17.37% from the prior year.
• Inventory Average slipped to $29.2 million in Q1 2026 per MYGN's latest filing, from $31.1 million in the prior quarter.
• Across five years, Inventory Average topped out at $31.1 million in Q4 2025 and bottomed at $15.4 million in Q1 2022.
• Historically, Inventory Average has averaged $24.0 million across 5 years, with a median of $23.8 million in 2023.
• Annual changes were most pronounced in 2022 — Inventory Average plunged 40.23% — and 2023, when it surged 42.9%.
• Myriad Genetics' Inventory Average stood at $19.8 million in 2022, then increased by 18.64% to $23.6 million in 2023, then increased by 14.01% to $26.8 million in 2024, then gained by 15.83% to $31.1 million in 2025, then fell by 5.95% to $29.2 million in 2026.
• Business Quant data shows MYGN's Inventory Average at $29.2 million in Q1 2026, $31.1 million in Q4 2025, and $30.2 million in Q3 2025.